Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Mst. M. Begum
Total Records ( 3 ) for Mst. M. Begum
  A. Sarwar , M.S. Rahman , T.B. Huq , K. Biswas , M.I. Hussain , J.F. Chaity , T. Begum , Md. E. Haque , A. Islam and Mst. M. Begum
  Background and Objective: To compare the prevalence of acute vomiting between patients receiving cisplatin as monotherapy or cisplatin in a combination regimen. Materials and Methods: The study was conducted at Delta Hospital Dhaka on a total of 70 patients (44 male and 26 female). The patients received either cisplatin alone or cisplatin with the following chemotherapeutic agents-docetaxel and 5 fluorouracil, docetaxel, etoposide, doxorubicin and capecitabine. The study was conducted in patients receiving chemotherapy for a total of the first 3 cycles. The patients were told to record the number of episodes of vomiting they experienced during the first 24 h after chemotherapy at each cycle. All 70 patients received prechemotherapy antiemetics a combination of 5HT3 receptor antagonist (ondansetron or palanosetron) and dexamethasone prior to chemotherapy. Results: In patients receiving the combination chemotherapy of cisplatin+docetaxel+5 FU experienced the lowest incidence of acute vomiting and cisplatin+capecitabine receiving patients experienced highest incidence of acute vomiting. All the other combination therapy resulted in emesis comparatively similar to that of cisplatin. In all the regimens except for cisplatin+etoposide the percentage of patients experiencing acute vomiting reduced along with progressive cycles. Conclusion: When cisplatin is given in combination regimen except for the combination regimen of cisplatin+capecitabine there is no significant increase in emesis between patients receiving cisplatin alone or in combination therapy.
  Mst. M. Begum , M.S. Rahman , R.R. Swarna , M. Das , A.H.M.R. Imon , I. Jahan , M. Rahman , Md. E. Haque , R.R. Saha , A.H.M. Quamruzzaman , Md. A. Obaida , M. Maniruzzaman , A. Islam , Md. T. Islam and A. Sarker
  Background and Objective: Combination of dosages regimen of an antidiabetic agent (Glibenclamide) with a lipid lowering drug can be an effective medication for the patient with high blood glucose level and liver enzyme disfunctionality. The present study was undertaken to investigate the effect of a fixed dose combination of glibenclamide (1.2 mg/70 kg b.wt.) and simvastatin (10 mg/70 kg b.wt.) on blood glucose and liver enzymes dysfuntionality in alloxan-induced diabetic rats for an extended time period. Materials and Methods: Two protocols were developed to carry out the experiment. The first is designated as 4 weeks short-term and second one is termed as 12 weeks long-term treatment protocols, respectively. Diabetes Mellitus (DM) was induced by single intraperitoneal (i.p.) injection of freshly prepared alloxan solution in 0.9% saline. Diabetic rats received treatment with i.p., injection of glibenclamide (1.2 mg/70 kg b.wt.) and simvastatin (10 mg/70 kg b.wt.) for 4 weeks as monotherapy and combination therapy (glibenclamide 0.6 mg/70 kg b.wt., simvastatin 5 mg/70 kg b.wt.) for 12 weeks. Graph pad was used and the results were expressed as Mean±SEM. A one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc test or students paired or unpaired t-test was used in the study where appropriate. Results: Results were considered to be significant when p-values were less than 0.05 (p<0.05). Combination therapy demonstrated a significant (p<0.05) decrease in blood glucose and liver enzymes elevation compared with diabetic control group. The study also demonstrated that the short term treatment has satisfactory effect on lowering SGPT by 41% and SGOT by 50%. Long term administration of combination therapy showed more significant (p<0.05) potentiality on lowering SGPT (46%) and SGOT (53%), respectively and this level remain steady during total treatment period. Conclusion: The present study demonstrates that combination of glibenclamide with simvastatin at the dose level tested exhibits significant glucose and liver enzymes lowering activity in alloxan induced diabetic rats. When monotherapy with oral antidiabetic agents fails, combination therapy with glibenclamide plus simvastatin seems to be stable and effective for the treatment of diabetes mellitus.
  A. Tabassum , R.R. Saha , M.S. Rahman , M.A. Nure , R. Karim , A.H.M.R. Imon , M. Maniruzzaman , A.K.L. Kabir , A. Islam , J.F. Chaity , B.C. Adhikary , A. Sarwar , T.B. Huq and Mst. M. Begum
  Background and Objective: Pain management has been an area of a great deal of attention for pharmacists for many years. In this study, we report a study which is designed to investigate how a combination of existing effective drugs performs for the relief of pain management. Materials and Methods: A combined solid dosage containing paracetamol (500 mg) and ibuprofen (150 mg) is developed and tested under an observational analytical study. The performance of this combined oral solid dosage named maxigesic tablet in order to reduce pain is investigated on the basis of European patent specification. This assay is carried out by employing HPLC system with UV detection at 222 nm. Results: The results show the presence of active components to the tune of 112.12% for paracetamol and 101.86% for ibuprofen. The formulated solid dosage is further subjected to separate groups of artificially pain induced mice for a comparative study and it shows more efficacy than single analgesic used in pain management. We observe that the respective potencies for paracetamol and ibuprofenare 98.57 and 102.90%. Conclusion: The characterization of both granules and tablets of newly developed formulation demonstrates significant improvement in results of analytical test that not only met the standard specification, but they also reveal that the combined dosage will improve the product quality, efficacy and patient safety in the long run. This trial also shows a significant difference in the percentage of pain inhibition between the two sets of formulations (single and combination of them).
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility